NCT00378131 - Placebo Controlled, Randomized Safety and Efficacy Study of RC-1291 in Cancer Anorexia/Cachexia | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 30, 2006

Primary Completion Date

April 30, 2007

Study Completion Date

April 30, 2007

Conditions

Cancer Cachexia

Interventions

DRUG

RC-1291

DRUG

placebo

Trial Locations (17)

10003

Beth Israel Cancer Center, New York

20817

Center for Cancer and Blood Disorders, Bethesda

21061

Chesapeake Oncology Hematology Associates, PA, Glen Burnie

23230

Virginia Cancer Institute, Richmond

24211

Cancer Outreach Associates, Abingdon

29210

South Carolina Oncology Associates, PA, Columbia

29406

Charleston Cancer Center, Charleston

29926

South Carolina Cancer Specialists, Hilton Head Island

32901

Melbourne Internal Medicine Associates, Melbourne

70503

Southwest Oncology Associates, Lafayette

77030

Michael E. DeBakey VA Medical Center, Houston

77555

University of Texas Medical Branch, Galveston

85304

Palo Verde Hematology Oncology, Ltd., Glendale

90403

Sant P. Chawla, MD, Santa Monica

92024

San Diego Pacific Oncology & Hematology Associates, Encinitas

98405

Multicare Health System, Tacoma

Northwest Medical Specialties, Tacoma

All Listed Sponsors

lead

Helsinn Therapeutics (U.S.), Inc

INDUSTRY